Biotechnology Innovation Organization (@IAmBiotech) header
Biotechnology Innovation Organization (@IAmBiotech) profile picture

I Am Biotech is where biotech professionals and enthusiasts can come together and discuss the promise of biotech innovation. #Biotech

Washington, DC
Joined January 2009
Photo by Biotechnology Innovation Organization (@IAmBiotech)Photo by Biotechnology Innovation Organization (@IAmBiotech)Photo by Biotechnology Innovation Organization (@IAmBiotech)Photo by Biotechnology Innovation Organization (@IAmBiotech)Photo by Biotechnology Innovation Organization (@IAmBiotech)Photo by Biotechnology Innovation Organization (@IAmBiotech)Photo by Biotechnology Innovation Organization (@IAmBiotech)Photo by Biotechnology Innovation Organization (@IAmBiotech)Photo by Biotechnology Innovation Organization (@IAmBiotech)Photo by Biotechnology Innovation Organization (@IAmBiotech)
For some rare diseases, the difference between a treatment that works and one that comes too late can come down to how early a baby is diagnosed. New therapies can now stop certain conditions before symptoms ever appear - but that window depends on catching them early. Read more on Bio.News: bio.news/latest-news/from-re…
2
3
544
Fifty years ago, when Bob Swanson and Dr. Herb Boyer founded Genentech in South San Francisco, the young company set out to prove that biology could be engineered into medicine. This past week, BIO’s President and CEO John F. Crowley joined @CLS_Advocacy at the 23rd Annual Pantheon Awards to present the first Industry Pioneer Award to @genentech. Genentech’s Chief Executive Officer, Ashley Magargee, accepted the award. The technology they pioneered has since saved the lives of millions - and it is still bringing hope to patients everywhere.
2
7
1,987
More than 30 biotech leaders. Two days in Washington. One ask for Congress: reauthorize the Pandemic and All-Hazards Preparedness Act (PAHPA) before year's end. This week, BIO members took biodefense priorities to Capitol Hill, making the case for stronger national health security, lasting public-private partnerships, and the medical countermeasures that keep Americans safe. Explore and download BIO's new PAHPA resource: bio.org/sites/default/files/…
3
903
Today's biotech race is our generation's Space Race. In his STAT+ opinion piece, BIO President and CEO John F. Crowley explains what's at stake in the global biotech race - and how BioAdvance, BIO’s newly released National action plan, offers a path forward. Read more in STAT: statnews.com/2026/11/10/chin…
1
4
1,056
At #BIOEurope2026 in Cologne, Team BIO spent three days connecting with companies ranging from early-stage startups to established innovators, hearing firsthand about where they’re headed, what stands in their way, and how BIO can help. And Team BIO didn’t shy away from the stage. Liz Gaskins opened BIO-Europe, while Chad Wessel led a session on the changing biopharma dealmaking landscape and the global trends shaping the industry. Those conversations and insights strengthen BIO’s work to advocate for an environment where biotech companies can grow, collaborate, and turn breakthroughs into real-world impact.
5
759
Today, BIO released BioAdvance, an action plan to ensure the United States remains the global biotech leader. By investing, innovating and acting with urgency, U.S. leaders can support the development of new medicines and secure another century of American biotech leadership. Read BioAdvance: bio.org/bioadvance
1
2
8
1,447
The policies enacted today will decide where the next generation of breakthroughs is developed. BIO President and CEO John F. Crowley says America's #biotech strength can't be taken for granted, and that now is the time to invest in the ecosystem driving jobs, growth and life-saving medicines for patients. Read the report: bio.org/jobs
3
705
Academic discoveries become jobs - and medicines - when companies build the teams, labs, and facilities to carry them forward. That happens in every state and region across the country. Full data in the @BayhDole Coalition's new report: bayhdolecoalition.org/new-re…
4
587
New data from BIO’s U.S. bioscience economy report with #CSBA and @TEConomyP_LLC points to what’s ahead for the industry. 📈 Companies have committed to U.S. biomanufacturing projects totaling hundreds of billions of dollars, many still in early building phases, and clinical trials were hosted in every state, D.C. and Puerto Rico from 2021 to 2025. Bio.News looks at what these trends mean for patients, innovators and states. Read the story: bio.news/state-policy/2026-r…
1
1
2
764
This year's #BIOPACE26 brought patient advocates, biotech leaders, and policy experts together in Washington, DC - and the momentum from those two days is still with us. Every advocate in the room represented a patient community, its stories, and the unmet needs that shape the path to new treatments. Thank you for your leadership, your partnership, and for making PACE what it was.
731
This fall, as we close out IP Month, we’re celebrating something as American as apple pie: the ideas that power American biotech. Strong intellectual property protections are the armor around every breakthrough, giving innovators the confidence to spend the decade-plus and billions it takes to turn an idea into a treatment. It’s also why small and emerging companies - behind the majority of new medicines - can attract the investment to compete at all. Read more on Bio.News: bio.news/federal-policy/ip-a…
1
3
672
The FDA has launched the Rare Disease Framework Initiative (“RDF Initiative”) to develop a fit-for-purpose regulatory framework to make drug development more predictable for conditions with small patient populations and limited data. Currently, about 95% of rare disease patients have no approved treatment. BIO presented recommendations at FDA’s Oct. 28 public meeting. Bio.News has the details: bio.news/federal-policy/bio-…
2
7
18
1,533
Before her diagnosis, Marci Pedrazzi McCue felt her body weakening and simple movements becoming harder. After receiving an investigational CAR-T cell therapy for MS at @stanfordmedbusa, she is reclaiming what MS once threatened to take. Patients like Marci are leading the #FightofOurLives. As she puts it: “I’m patient one. That means that there’s going to be more and that there needs to be more.” See Marci’s full story: fightofourlives.com/stories/… #MultipleSclerosis #BiotechInnovation
2
6
964
BIO welcomes four newly elected members to our Board of Directors. Their leadership will help advance our mission to protect patient access, defend the innovation ecosystem, and cement biotech’s role as a cornerstone of America’s health, economic, and national security. Please join us in welcoming the newest members of BIO’s Board: - Nelson Ambrogio, President, U.S. Pharmaceuticals, @BayerUS - Peter Norman, Senior Vice President, Policy & Government Relations, Alkermes - Tom Scales, Senior Vice President, Market Access & Public Affairs, @novonordisk - Nancy C. Whiting, Chief Executive Officer, Recludix Pharma #BiotechLeadership #BiotechInnovation
1
5
754
Between 2021-2025, America's #bioscience industry generated $3.19 trillion in total economic output, according to a new report BIO launched in partnership with #CSBA and @TEConomyP_LLC. Read the report: bio.org/jobs
2
1
3
572
The 12th edition of the report shows how the industry is strengthening economies at the national, state and local levels, with new insights on biomanufacturing, clinical trials and more. Fact sheets are available for all 50 states, D.C. and Puerto Rico.
1
300
Trust in science starts with transparency. Caitlin Grzeskowiak, Chief Research and Innovation Officer at the @EpilepsyFdn addresses what it means to translate complex science for patients and meeting them where they are. Caitlin participated in a #BIOPACE26 panel on trust in science last week, moderated by BIO Executive Vice President and Chief of Global Health Phyllis Arthur. Both were joined by Sean Clements, Principal at SPC Strategies, and Amar Duggirala, Board Chair and Immediate Past President of the Maryland Academy of Family Physicians.
2
1
1
942
A meaningful step forward for the 2.1 million Americans living with schizophrenia -> Congratulations to @TevaUSA on FDA approval of Weltruza - the first once-monthly olanzapine injection given under the skin, with no post-dose monitoring required.
BREAKING: The FDA has granted approval of our new schizophrenia long-acting treatment option. Read more from today’s announcement here: ow.ly/9sjW50ZWenA $TEVA
2
1,049
A new report from @BayhDole Coalition shows how far university discoveries travel once they reach the market, building on BIO and @AUTM's 2022 analysis with five more years of data. The findings: the Bayh-Dole Act has fueled thousands of startups and new products - and moved discoveries out of the lab and to the patients using them today. Read more on Bio.News: bio.news/federal-policy/bayh…
1
2
643